Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.
Translational Lung Cancer Research
Santarpia, Mariacarmela M; Ciappina, Giuliana G; Spagnolo, Calogera Claudia CC; Squeri, Andrea A; Passalacqua, Maria Ilenia MI; Aguilar, Andrés A; Gonzalez-Cao, Maria M; Giovannetti, Elisa E; Silvestris, Nicola N; Rosell, Rafael R
Combined KRAS G12C and SOS1 inhibition enhances and extends the anti-tumor response in KRAS G12C -driven cancers by addressing intrinsic and acquired resistance.
Biorxiv : The Preprint Server For Biology
Thatikonda, Venu V; Lu, Hengyu H; Jurado, Sabine S; Kostyrko, Kaja K; Bristow, Christopher A CA; Bosch, Karin K; Feng, Ningping N; Gao, Sisi S; Gerlach, Daniel D; Gmachl, Michael M; Lieb, Simone S; Jeschko, Astrid A; Machado, Annette A AA; Marszalek, Ethan D ED; Mahendra, Mikhila M; Jaeger, Philipp A PA; Sorokin, Alexey A; Strauss, Sandra S; Trapani, Francesca F; Kopetz, Scott S; Vellano, Christopher P CP; Petronczki, Mark M; Kraut, Norbert N; Heffernan, Timothy P TP; Marszalek, Joseph R JR; Pearson, Mark M; Waizenegger, Irene I; Hofmann, Marco H MH
In Silico Study of the Acquired Resistance Caused by the Secondary Mutations of KRAS G12C Protein Using Long Time Molecular Dynamics Simulation and Markov State Model Analysis.
Enhancing an Oxidative "Trojan Horse" Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside.
Cells
Burska, Agata N AN; Ilyassova, Bayansulu B; Dildabek, Aruzhan A; Khamijan, Medina M; Begimbetova, Dinara D; Molnár, Ferdinand F; Sarbassov, Dos D DD
Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance.
Cancers
Ashrafi, Adnin A; Akter, Zakia Z; Modareszadeh, Pouya P; Modareszadeh, Parsa P; Berisha, Eranda E; Alemi, Parinaz Sadat PS; Chacon Castro, Maria Del Carmen MDC; Deese, Alexander R AR; Zhang, Li L
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Cancer Discovery
Weiss, Andreas A; Lorthiois, Edwige E; Barys, Louise L; Beyer, Kim S KS; Bomio-Confaglia, Claudio C; Burks, Heather H; Chen, Xueying X; Cui, Xiaoming X; de Kanter, Ruben R; Dharmarajan, Lekshmi L; Fedele, Carmine C; Gerspacher, Marc M; Guthy, Daniel Alexander DA; Head, Victoria V; Jaeger, Ashley A; Núñez, Eloísa Jiménez EJ; Kearns, Jeffrey D JD; Leblanc, Catherine C; Maira, Sauveur-Michel SM; Murphy, Jason J; Oakman, Helen H; Ostermann, Nils N; Ottl, Johannes J; Rigollier, Pascal P; Roman, Danielle D; Schnell, Christian C; Sedrani, Richard R; Shimizu, Toshio T; Stringer, Rowan R; Vaupel, Andrea A; Voshol, Hans H; Wessels, Peter P; Widmer, Toni T; Wilcken, Rainer R; Xu, Kun K; Zecri, Frederic F; Farago, Anna F AF; Cotesta, Simona S; Brachmann, Saskia M SM
KRAS is vulnerable to reversible switch-II pocket engagement in cells.
Nature Chemical Biology
Vasta, James D JD; Peacock, D Matthew DM; Zheng, Qinheng Q; Walker, Joel A JA; Zhang, Ziyang Z; Zimprich, Chad A CA; Thomas, Morgan R MR; Beck, Michael T MT; Binkowski, Brock F BF; Corona, Cesear R CR; Robers, Matthew B MB; Shokat, Kevan M KM
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.
The Journal Of Clinical Investigation
Tsai, Yihsuan S YS; Woodcock, Mark G MG; Azam, Salma H SH; Thorne, Leigh B LB; Kanchi, Krishna L KL; Parker, Joel S JS; Vincent, Benjamin G BG; Pecot, Chad V CV
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.
The Journal Of Clinical Investigation
Tsai, Yihsuan S YS; Woodcock, Mark G MG; Azam, Salma H SH; Thorne, Leigh B LB; Kanchi, Krishna L KL; Parker, Joel S JS; Vincent, Benjamin G BG; Pecot, Chad V CV